Please ensure Javascript is enabled for purposes of website accessibility

Why Genomic Health, Inc. Earned a Higher Share Price

By Brian Orelli, PhD - May 5, 2016 at 12:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A solid earnings report gives the cancer-test maker's stock a boost.

What: Genomic Health (GHDX) is up 11% at 12 p.m. ET after reporting solid earnings following the bell yesterday.

So what: Revenue increased 19% year over year while tests delivered increased 16%. Revenue is growing faster than test volume because Genomic Health is being reimbursed for more of its tests, which is obviously a good thing.

While Genomic Health's prostate cancer test remains its best opportunity for near-term growth, it only contributed $2.6 million of the $70.5 million in U.S. growth and provided 4 percentage points of the 22% increase in stateside revenue.

While those numbers would seem to point toward slow growth, the number of prostate tests delivered grew 18% compared to the year-ago quarter, so the test is increasingly being used by doctors, but reimbursement is still an issue. In fact, only about half of the eligible Medicare revenue was captured in the first quarter. "We expect our ongoing efforts to collect required data for Medicare billing to result in a higher conversion of tests to revenue in future quarters," according to Brad Cole, Genomic Health's COO and CFO.

Most of the growth in the U.S. came from invasive breast cancer tests, which grew 17% year over year. The increase came both from an 11% increase in volume thanks to the prospective outcomes data presented last year and increased reimbursement.

Now what: Genomic Health isn't profitable yet, but it's moving in the right direction. Operating loss for the quarter was $8.8 million, and the second-quarter operating loss should improve compared to the first quarter as expenses come down since the first quarter had bonuses and other one-time expenses.

The second quarter tends to be a softer one for tests, so Genomic Health is looking for flat revenue quarter over quarter, which would result in double-digit growth compared to the second quarter of 2015.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Genomic Health, Inc. Stock Quote
Genomic Health, Inc.
GHDX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.